Cont. from page xxxiv.

mechanisms of resistance using PDO and pretreatment biopsy specimen

Exploratory Research

- Evaluate PFS, safety and tolerability, ORR, DCR, and OS in patients who received prior treatment with 5-FU independently from the entire population

Contact: Amit Mahipal, MBBS, MPH • 612-298-5401 • mahipal.amit@mayo.edu

Coordinator: Jaclyn Wessling, MS • 507-538-4545 • wessling.jaclynn@mayo.edu

ClinicalTrials.gov Identifier: NCT04072445

ERRATUM

Erratum to: Abu-Rustum et al. NCCN Guidelines Insights on Uterine Neoplasms, Version 3.2021. J Natl Compr Canc Netw 2021;19(8):888–895.

In the August 2021 issue of *JNCCN*, the NCCN Guidelines Insights on Uterine Neoplasms, Version 3.2021 (J Natl Compr Canc Netw 2021;19[8]:888–895) was published with an error.

The list of supporters for the Continuing Education Activity, printed on page 888, was incorrect. The correct list of supporters should read: This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics.

A corrected copy of the article is available online at [JNCCN.org](https://www.jnccn.org). The editorial office apologizes for this error.

doi: 10.6004/jnccn.2021.0052